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Patients with fibrotic sarcoidosis can develop worsening of pulmonary symptoms for various
reasons. We studied acute worsening events defined as episodes treated with limited courses
of either antibiotics and or increased corticosteroid doses which resolved within four weeks.
The prevalence of acute worsening events in patients with fibrotic sarcoidosis was investi-
gated. Of 740 sarcoidosis patients seen in our clinic over a four month period, 129 (17%)
had fibrotic sarcoidosis. We noted the age, race, gender, computer tomography (CT) results,
and pulmonary function as measured by forced vital capacity (FVC), forced expiratory volume
in one second (FEV1), and the FEV1/FVC ratio. In a retrospective manner, the fibrotic sarcoid-
osis patients reported a median of three acute worsening events (range zero to eight) in the
prior year. Bronchiectasis was noted on CT imaging in 63 of 129 (49%) of the fibrotic sarcoid-
osis patients. Fibrotic sarcoidosis patients reported a higher frequency of acute worsening
events (3 (0e6)) than those without bronchiectasis (2 (0e8), p Z 0.0001). Sixteen patients
receiving anti-tumor necrosis factor antibodies reported a higher frequency of acute wors-
ening events compared to those not receiving anti-tumor necrosis factor antibodies
(p Z 0.0297). There was no relationship between the number of acute worsening events
and race, gender, smoking history, or FVC, FEV1, or FEV1/FVC ratio. We conclude that acute
worsening events are frequent in patients with fibrotic sarcoidosis patients and are more
common in patients with bronchiectasis and those receiving anti-tumor necrosis factor anti-
body therapies.
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Table 1 Demographics of fibrotic sarcoidosis patients
studied.
Total
Number 129
Female:Male 92/37
Black:White 78/51
Age years 57 (35e87)a
Disease duration, years 13 (1e42)
FVC, l 2.57 (1.11e5.43)
FVC % predicted 79 (33e131)%
FEV1, l 1.90 (0.77e3.51)
FEV1 % predicted 56 (17e106)%
FEV1/FVC % 73 (35e100)%
DLCO 17.5 (7.68e41.56)
DLCO % predicted 74 (37e128)%
Smoking history
Current/Prior/Nonsmokers 16/33/80
Bronchiectasis
Yes/No 63/66
Acute worsening events in prior year 3 (0e8)
a Median (Range).
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Pulmonary sarcoidosis patients can develop episodes of
acute worsening of pulmonary symptoms. While this can
occur in all stages of pulmonary sarcoidosis, an acute
worsening in fibrotic sarcoidosis patients can result in sig-
nificant pulmonary morbidity. There are several causes of
acute worsening of pulmonary sarcoidosis, including wors-
ening of the underlying sarcoidosis, infection, acute bron-
chospasm, or extra-pulmonary causes [1].
Relapse of sarcoidosis can occur during reduction or
withdrawal of corticosteroids and/or other systemic ther-
apy for pulmonary sarcoidosis [2,3]. This event has been
termed an acute pulmonary exacerbation of sarcoidosis [1].
Patients with acute pulmonary exacerbation of sarcoidosis
will often respond to reinstitution or an increase in corti-
costeroid dosage [4]. Patients relapsing during corticoste-
roid withdrawal are usually maintained on long term
immunosuppressive therapy to prevent further relapses
[2,3,5].
Acute pulmonary worsening can also occur in patients
receiving stable doses of treatment. These episodes are
often related to infection, and patients may respond to a
short course of corticosteroids and broad spectrum antibi-
otics. Because resolution usually occurs in less than 4
weeks, these episodes are considered unique from acute
pulmonary exacerbations of sarcoidosis [1]. In addition to
infection, patients can also develop airway reactivity that
responds to short courses of corticosteroid therapy [6].
Disease worsening can cause significant morbidity in
patients with fibrotic sarcoidosis. In order to better un-
derstand the frequency and associated features of acute
worsening of fibrotic sarcoidosis, we studied patients seen
at the University of Cincinnati Sarcoidosis Clinic.
Methods
Patients were recruited from those seen at the University
of Cincinnati Interstitial Lung Disease and Sarcoidosis
Clinic. Patients with sarcoidosis based on ATS/ERS/WASOG
criteria who had chest imaging consistent with pulmonary
fibrosis were eligible for evaluation. This retrospective
study was part of an ongoing investigation of pulmonary
infections in sarcoidosis and it was approved by the Uni-
versity of Cincinnati Institutional Review Board. This
study examined a subset of sarcoidosis patients with
pulmonary fibrosis seen during a four month period in our
clinic. The presence of pulmonary fibrosis was decided by
the radiologist who made the official interpretation of
prior chest X-ray and high resolution CT (HRCT) scan
which were performed as part of routine evaluation of the
patient’s sarcoidosis. Although we reviewed these films,
we chose to use the radiologist interpretation. All pa-
tients had both a routine chest X-ray and HRCT scan to
review.
Acute worsening was defined as an episode in which the
patient was either prescribed an antibiotic for 5e21 days
and/or a short increase in systemic glucocorticoids for
increased cough and/or dyspnea. Although some patients
underwent chest roentgenograms during these episodes, an
abnormal imaging was not required.During a four month period, each fibrotic sarcoidosis
patient was asked to estimate the number of acute wors-
ening events that had occurred during the prior twelve
months. When possible, this number was verified by chart
review.
In addition to the number of episodes, additional de-
mographic information including age, gender, self-declared
race, smoking history, and sarcoidosis duration and organ
involvement was recorded from the chart review. Chest
imaging was reviewed for the presence or absence of
bronchiectasis along with the most recent pulmonary
function tests including FEV1, FVC, and FEV1/FVC ratio and
the predicted values [7]. Current and past systemic
sarcoidosis medications were categorized as glucocorti-
coids, cytotoxic drugs such as methotrexate, leflunomide,
and azathioprine, and anti-tumor necrosis factor (TNF)
monoclonal antibodies infliximab and adalimumab. Since
the dosage of prednisone varied over the course of the year
of study for most patients, we were not able to calculate an
average dose of prednisone.
Statistics: The distribution of acute worsening events
was not normally distributed and therefore the Mann
Whitney U test, Spearman Rank, and other non-parametric
tests were used. A p value of less than 0.05 was considered
significant.
Results
During the four month period of the study from May to
September 2012, 740 patients with sarcoidosis were seen in
the Interstitial Lung Disease and Sarcoidosis Clinic. A total
of 129 (17%) sarcoidosis patients with pulmonary fibrosis
were studied. Of these, 63 (49%) had bronchiectasis iden-
tified on chest imaging, usually high resolution computer
tomography (HRCT). Table 1 summarizes the demographics
of the patients enrolled in the study, including age, race,
gender, disease duration, pulmonary function studies,
Table 2 Comparison of patients with or without
bronchiectasis.
Bronchiectasis No bronchiectasis
Number 63 66
Female:Male 44/19 48/18
Black:White 37/26 41/25
Age years 57 (35e87)a 56 (39e75)a
Disease duration,
years
11 (1e42) 14.5 (1e39)
FVC, l 2.70 (1.35e5.00) 2.35 (1.11e5.43)
FVC % predicted 82 (34e131)% 78 (33e110)%
FEV1, l 1.96 (0.77e3.32) 1.80 (0.89e3.59)
FEV1/FVC % 73 (42e89)% 73 (35e100)%
DLCO 16.9 (7.68e33.88) 17.7 (7.70e41.56)
DLCO % predicted 70 (38e128)% 77 (37e103)%
Smoking history
Current/Prior/
Nonsmokers
8/15/40 8/18/40
Acute worsening
events in
prior year
3 (0e6) 2 (0e8)b
a Median (Range).
b Differs from bronchiectasis, p Z 0.0001.
Acute events in fibrotic sarcoidosis 2011serum IgE level, and number of acute worsening events in
the past year.
Ninety-four (73%) of patients reported two or more
acute worsening events in the past year with the median
number of acute worsening events three with range from
0 to 8. No significant correlation was noted between num-
ber of acute worsening events and age, FVC, FVC % pre-
dicted, FEV1,FEV1% predicted, FEV1/FVC, or DLCO %
predicted. We did not have lung volumes on all patients, so
could not analyze residual volume or total lung capacity %
predicted versus number of events. Additionally, there was
no difference in the number of acute worsening events
based on race or gender or among current smokers, prior
smokers, and nonsmokers.
However, patients with bronchiectasis on HRCT experi-
enced a higher number of acute worsening events (3 (0e6))
compared to those without bronchiectasis (2 (0e8),
p Z 0.0001) (Fig. 1). Table 2 compares the demographic
features of those patients with or without bronchiectasis.
There was no significant difference between the presence
of bronchiectasis and gender, race, age, FVC, FVC % pre-
dicted, FEV1, FEV1/FVC, DLCO, DLCO % predicted, or
smoking history.
Table 3 summarizes patient’s current and prior sarcoid-
osis treatments. Patients could receive more than one
therapy, and 34 patients received no immunosuppressants
during the study period. There was no difference in the
frequency of acute worsening events for those patients
receiving prednisone, methotrexate, or azathioprine. The
eight patients receiving leflunomide were significantly
more likely to have experienced acute events in the prior
year. In addition, the 16 patients receiving anti-TNF anti-
bodies experienced significantly higher number of acute
worsening events compared to those who had never
received anti-TNF therapies (N Z 16,p Z 0.0297). Fig. 2
demonstrates the number of acute worsening events for
those patients. There was no significant difference in pul-
monary function or the rate of bronchiectasis for those
receiving or not receiving anti-TNF antibodies. This would
suggest that pulmonary function tests alone are notFigure 1 Number of acute worsening events in prior year for
those with or without bronchiectasis. Patients with bronchi-
ectasis were more likely to have acute worsening events
(p Z 0.0001).sufficient to identify severity of sarcoidosis or which pa-
tients are more likely to have acute worsening events.Discussion
We conclude that acute worsening events occur frequently
in patients with fibrotic sarcoidosis. Although these epi-
sodes were correlated with underlying bronchiectasis,
acute events were not associated with race, gender, age,
smoking history, or underlying airway obstruction. Patients
who received anti-TNF therapies experience higher rates of
acute worsening events, which may reflect more severe
pulmonary disease or increased immunosuppression in
these patients.Table 3 Systemic therapy for sarcoidosis versus number
of acute worsening events in prior year.
Total Number of acute
worsening events
in prior year
Number 129 3 (0e8)a
Current prednisone 79 (61%)b 3 (0e8)
Current methotrexate 35 (27%) 3 (0e8)
Current azathioprine 14 (11%) 2.5 (1e4)
Current leflunomide 8 (6%) 4 (2e6)c
Current anti-TNF therapy 16 (12%) 3.5 (1e6)c
Current or past
anti-TNF therapy
29 (22%) 3 (1e8)c
No therapy 34 (26%) 3 (0e6)
a Median (Range).
b Number (percent of total).
c Differs from those not on therapy, p < 0.05.
Figure 2 Number of acute worsening events in prior year for
those receiving anti-TNF antibody (N Z 16) versus not
currently receiving anti-TNF antibody (p Z 0.0364).
2012 R.P. Baughman, E.E. LowerThere is no standard definition for an acute exacerbation
that occurs in sarcoidosis patients [1]. Because of concerns
about disease progression, we chose to limit our study to
fibrotic sarcoidosis patients who usually require chronic
therapy with minimal dosage changes over time [5]. Most
patient reported events did not represent disease wors-
ening since the events were usually not preceded by a
treatment reduction and they were limited to four weeks of
additional therapy without increased immunosuppression.
It has been suggested that acute sarcoidosis exacerbations
as defined by a decline in FVC of >10% may respond to short
course of increased corticosteroids [4]. However, it is un-
clear if all patients have disease worsening since the events
are often unaccompanied by any chest roentgenogram
changes [8]. Patients with pulmonary fibrosis usually have
restrictive lung disease, but an obstructive component can
be seen [9,10]. The average FEV1/FVC ratio was 73% in this
study, the same as that reported in a large study of stage 4
sarcoidosis patients followed in France [11].
For this group of patients, acute worsening was likely
was related to an infection rather than other causes. Our
definition of acute worsening required that patients
receive antibiotics for the episode since our practice is to
prescribe a short antibiotic course for one or more
symptoms of increased dyspnea, sputum volume, or
sputum purulence [12]. For patients with chronic
obstructive pulmonary disease (COPD), the official ATS/
ERS statement says: An exacerbation of COPD is an event
in the natural course of the disease characterized by a
change in the patient’s baseline dyspnea, cough and/or
sputum beyond day-to-day variability sufficient to warrant
a change in management [13]. Risk factors for acute
exacerbation chronic bronchitis (AECB) in chronic
obstructive pulmonary disease (COPD) include physician
diagnosed asthma [14] and low FEV1 [15,16], and smoking
history does not seem to influence the rate of AECB in
COPD patients [14,15]. In the current study, smoking his-
tory was also not associated with an increased rate of
acute worsening events. We also feel that the response to
a short course of increased prednisone (5e21 days) was a
reflection of bacterial infection rather than sarcoidosis
itself. While others have found that short coursecorticosteroid therapy may improve underlying sarcoidosis
[4], our practice is to give a more prolonged course of
corticosteroids for those patients we believe are suffering
from a worsening of their underlying sarcoidosis.
The presence of chronic cough and sputum are risk
factors for AECB in COPD patients [15,16], and these are the
clinical features of patients with bronchiectasis. Studying
moderate to severe COPD patients with HRCT, Patel et al.
identified bronchiectasis in half of their study patients [17].
In COPD, the finding of bronchiectasis on HRCT was asso-
ciated with more prolonged recovery from the exacerba-
tion, but not a change in frequency of AECB events [17]. In
the current study, we found that patients with bronchiec-
tasis were more likely to have acute worsening events.
Bronchiectasis is a complication of fibrotic sarcoidosis
[18,19]. Bronchiectasis will not improve with anti-
inflammatory treatments, although other inflammatory
changes around the area of bronchiectasis may improve
with therapy [19]. The presence of bronchiectasis is asso-
ciated with aspergillomas, a severe complication of
sarcoidosis [20]. Bronchiectasis is also associated with
increased colonization of bacteria and a source of repeat
infection [17]. In the current study, patients with evidence
of bronchiectasis on HRCT scan experienced a higher rate of
acute worsening events.
Additionally, the use of immunosuppression may lead to
higher infection rates.We noted that patients receiving anti-
TNF antibodies developed higher rates of acute worsening
events. This could relate to the immunosuppression associ-
atedwith anti-TNF antibodies. Use of anti-TNF antibodies for
rheumatoid arthritis is associated with an increased rate of
serious infections from organisms such as Mycobacteria
tuberculosis as well as bacterial infections [21,22]. Patients
receiving infliximab may also develop an increased risks for
influenza and influenza-like illnesses which could lead to an
acute worsening event [23]. However, the rate of compli-
cated respiratory infections appears unchanged for those
treated with anti-TNF antibodies. In one large study of
rheumatoid arthritis patients, therewas no increased risk for
patients hospitalized for bronchitis compared to patients
receiving other immunosuppressants [24]. Hence, it is
possible that the increased rate of acute worsening events
may reflect of more severe underlying pulmonary disease in
these patients. However, no difference was identified in the
pulmonary function status or rate of bronchiectasis between
those receiving or not receiving anti-TNF antibodies.
There are several potential limitations of our study. We
chose to use the official radiologic interpretation to iden-
tify pulmonary fibrosis. We did not re-review all the films,
nor did we have two readers evaluate all films to provide a
kappa. We have previously determined that review of chest
x-ray may identify some variability in the detection of
pulmonary fibrosis in sarcoidosis patients [25]. There may
be less variability when evaluating fibrosis using HRCT. The
diagnosis of an acute worsening event was retrospective
and based on patient recall, although we did try to verify
these events by review of the patient’s chart. These events
may have represented acute worsening of the sarcoidosis
rather than infections. Since we were unable to calculate
an average prednisone dose during the year of the study,
we could not evaluate the effect of prednisone dosage on
the frequency of acute worsening events.
Acute events in fibrotic sarcoidosis 2013We conclude that acute worsening events were more
likely to occur in fibrotic sarcoidosis patients with under-
lying bronchiectasis who were receiving anti-TNF antibody
therapy. These associations would suggest that acute
worsening events in fibrotic sarcoidosis patients were more
likely infections. In these patients, treatment with antibi-
otics and/or short term increases in corticosteroid therapy
was usually associated with symptomatic improvement.
Treatments which can minimize the episodes of acute
worsening events may improve the quality of life of pul-
monary sarcoidosis patients with fibrosis.Conflict of interest
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